CN109890843A - 一种abcg2单克隆抗体及其用途 - Google Patents

一种abcg2单克隆抗体及其用途 Download PDF

Info

Publication number
CN109890843A
CN109890843A CN201780056711.2A CN201780056711A CN109890843A CN 109890843 A CN109890843 A CN 109890843A CN 201780056711 A CN201780056711 A CN 201780056711A CN 109890843 A CN109890843 A CN 109890843A
Authority
CN
China
Prior art keywords
antibody
abcg2
cell
sequence
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201780056711.2A
Other languages
English (en)
Other versions
CN109890843B (zh
Inventor
甄红英
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Peking University
Original Assignee
Peking University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Peking University filed Critical Peking University
Publication of CN109890843A publication Critical patent/CN109890843A/zh
Application granted granted Critical
Publication of CN109890843B publication Critical patent/CN109890843B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

公开了兼具抗肿瘤及逆转肿瘤抗药性作用的ABCG2单克隆抗体及其在作为新型抗肿瘤药物中的用途。还公开了一种新的抗原序列，其用于诱导产生针对ABCG2的单克隆或者多克隆抗体的产生。另外，公开了产生兼具抗肿瘤及逆转肿瘤抗药性作用的ABCG2单克隆抗体的杂交瘤。

Description

PCT国内申请，说明书已公开。

Claims (15)

  1. PCT国内申请，权利要求书已公开。
CN201780056711.2A 2016-09-14 2017-09-13 一种abcg2单克隆抗体及其用途 Active CN109890843B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201610827464.9A CN106432490B (zh) 2016-09-14 2016-09-14 一种abcg2单克隆抗体及其用途
CN2016108274649 2016-09-14
PCT/CN2017/101549 WO2018050066A1 (zh) 2016-09-14 2017-09-13 一种abcg2单克隆抗体及其用途

Publications (2)

Publication Number Publication Date
CN109890843A true CN109890843A (zh) 2019-06-14
CN109890843B CN109890843B (zh) 2022-06-17

Family

ID=58168146

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201610827464.9A Active CN106432490B (zh) 2016-09-14 2016-09-14 一种abcg2单克隆抗体及其用途
CN201780056711.2A Active CN109890843B (zh) 2016-09-14 2017-09-13 一种abcg2单克隆抗体及其用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201610827464.9A Active CN106432490B (zh) 2016-09-14 2016-09-14 一种abcg2单克隆抗体及其用途

Country Status (3)

Country Link
US (1) US10611847B2 (zh)
CN (2) CN106432490B (zh)
WO (1) WO2018050066A1 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106432490B (zh) 2016-09-14 2020-01-07 北京大学 一种abcg2单克隆抗体及其用途
AU2018348165A1 (en) * 2017-10-10 2020-05-21 Gritstone Bio, Inc. Neoantigen identification using hotspots
CN108342488B (zh) * 2018-05-14 2021-02-19 银丰基因科技有限公司 一种用于检测胃癌的试剂盒
US20230212305A1 (en) * 2020-06-04 2023-07-06 Kenjockety Biotechnology, Inc. Anti-abcg2 antibodies and uses thereof
CN116529267A (zh) * 2020-06-04 2023-08-01 肯乔克蒂生物技术股份有限公司 Abcg2外排泵-癌症抗原多特异性抗体及其相关组合物、试剂、试剂盒和方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000069390A2 (en) * 1999-05-17 2000-11-23 Cancer Research Ventures Limited Compositions for improving bioavailability of orally administered drugs
US20050186610A1 (en) * 2004-02-20 2005-08-25 Yeon-Su Lee Breast cancer related protein, gene encoding the same, and method of diagnosing breast cancer using the protein and gene
US20060160139A1 (en) * 2005-01-18 2006-07-20 Naoko Takebe Rhesus BCRP and antibodies thereto
US20090208493A1 (en) * 2007-11-27 2009-08-20 Stc. Unm Compounds and methods for the selective inhibition of ABCB1, ABCC1 and ABCG2 transporters and the treatment of cancers, especially drug resistant cancers and high throughput flow cytometry assay to detect selective inhibitors
US20110256053A1 (en) * 2005-04-06 2011-10-20 Immunomedics, Inc. Multiple Signaling Pathways Induced by Hexavalent, Monospecific and Bispecific Antibodies for Enhanced Toxicity to B-Cell Lymphomas and Other Diseases
CN103562403A (zh) * 2011-02-22 2014-02-05 北京市肿瘤防治研究所 识别肿瘤起始细胞的抗体和抗原及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000036101A2 (en) 1998-11-30 2000-06-22 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services An atp-binding cassette protein responsible for cytotoxin resistance
EP1323735A4 (en) * 2000-10-03 2005-02-09 Banyu Pharma Co Ltd GENE RELATING TO DRUG TOLERANCE AND USE THEREOF
WO2007037782A2 (en) 2005-02-08 2007-04-05 The University Of North Carolina At Chapel Hill Method for treating prostate conditions
WO2009061770A2 (en) * 2007-11-07 2009-05-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of inhibiting abcg2 and related treatments
CN101724072B (zh) * 2008-10-27 2013-10-09 谷为岳 一种抗肿瘤的单克隆抗体的序列及应用
CN104513297B (zh) 2013-09-27 2018-12-04 李光辉 用于筛选抗癌症医药组合物的多肽分子及其应用
CN106432490B (zh) 2016-09-14 2020-01-07 北京大学 一种abcg2单克隆抗体及其用途

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000069390A2 (en) * 1999-05-17 2000-11-23 Cancer Research Ventures Limited Compositions for improving bioavailability of orally administered drugs
US20050186610A1 (en) * 2004-02-20 2005-08-25 Yeon-Su Lee Breast cancer related protein, gene encoding the same, and method of diagnosing breast cancer using the protein and gene
US20060160139A1 (en) * 2005-01-18 2006-07-20 Naoko Takebe Rhesus BCRP and antibodies thereto
US20110256053A1 (en) * 2005-04-06 2011-10-20 Immunomedics, Inc. Multiple Signaling Pathways Induced by Hexavalent, Monospecific and Bispecific Antibodies for Enhanced Toxicity to B-Cell Lymphomas and Other Diseases
US20090208493A1 (en) * 2007-11-27 2009-08-20 Stc. Unm Compounds and methods for the selective inhibition of ABCB1, ABCC1 and ABCG2 transporters and the treatment of cancers, especially drug resistant cancers and high throughput flow cytometry assay to detect selective inhibitors
CN103562403A (zh) * 2011-02-22 2014-02-05 北京市肿瘤防治研究所 识别肿瘤起始细胞的抗体和抗原及其应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
李勇等: "纳米粒子在肿瘤干细胞治疗方面的研究进展", 《现代生物医学进展》 *

Also Published As

Publication number Publication date
US10611847B2 (en) 2020-04-07
CN106432490B (zh) 2020-01-07
CN106432490A (zh) 2017-02-22
US20190248912A1 (en) 2019-08-15
WO2018050066A1 (zh) 2018-03-22
CN109890843B (zh) 2022-06-17

Similar Documents

Publication Publication Date Title
US11155632B2 (en) Anti-CD47 monoclonal antibody and use thereof
CN110627906B (zh) 抗pd-l1/4-1bb双特异性抗体及其用途
TWI708788B (zh) 雙特異性抗體
CN109890843A (zh) 一种abcg2单克隆抗体及其用途
US20230021388A1 (en) Anti-ror1 antibodies and compositions
US20220356246A1 (en) Anti-ROR1 antibodies and preparation method and uses thereof
CN113710271A (zh) 抗cd228抗体和抗体-药物缀合物
BR112020014848A2 (pt) Anticorpo anti-4-1bb, fragmento de ligação ao antígeno do mesmo e uso médico do mesmo
CN112111008A (zh) 抗cd73抗体及其应用
CN115109160B (zh) 抗epcam抗体和双特异性抗体
WO2022171134A1 (zh) 包含抗cldn18.2的抗体或其抗原结合片段的抗体药物偶联物及其用途
CN105385694A (zh) 抗人cd98单克隆抗体98-3h3轻、重链可变区基因及其应用
JP2024514855A (ja) Ｄｌｌ３に対する結合分子及びその使用
CN117897407A (zh) 抗Nectin-4抗体、药物缀合物及其制备方法和用途
WO2021047386A1 (zh) 靶向caix抗原的纳米抗体及其应用
CN115960240A (zh) 一种同时靶向人bcma和人cd3的双特异性抗体
CN114685670A (zh) Cldn18.2抗体及其应用
CN114316045A (zh) 抗pd-l1抗体及其用途
CN107163146B (zh) 一种靶向人肿瘤干细胞的单克隆抗体及其应用
CN113321730B (zh) Cldn18.2抗体及其应用
CN114539415B (zh) 一种抗PD-L1/VEGF/TGF-β多特异性抗体及其用途
CN115124621B (zh) 靶向pd-l1的纳米抗体及其制备方法和应用
WO2022068809A1 (zh) 抗cd3抗体以及其用途
WO2024131835A1 (en) Ligand-cytotoxicity drug conjugates and pharmaceutical uses thereof
WO2023142297A1 (zh) Muc1结合分子及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant